SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a sharp selloff tied to reports that OpenAIs latest Ultrafast mode uses Nvidia GPUs, raising questions about Cerebras role with its key customer, alongside staged IPO share unlocks and insider selling that traders see as added supply pressure. Bulls cite Sam Altmans reaffirmation of the partnership and argue the Nvidia use may reflect capacity constraints rather than lost business, while bears remain concerned about competition and further share sales.

Select Sector SPDR Trust (The) - State Street Utilities Select Sector SPDR ETF

Utilities Select Sector SPDR Fund

XLU is drawing attention for a potential rebound after a steep utilities-sector selloff, with traders pointing to unusually active call options and bullish positioning. The recovery remains contested because utilities are rate-sensitive: some see a bottom forming, while others warn that stubborn Treasury yields could keep pressure on the fund.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Real-world DefenCath findings presented around ASN Kidney Week are driving discussion: traders highlight reported reductions in bloodstream infections and hospitalizations, while a Fresenius comparison found no significant difference versus ClearGuard. The mixed evidence has fueled debate about DefenCaths clinical and commercial outlook amid ongoing concern about reimbursement and the share-price decline.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp, high-volume breakout with no confirmed company announcement is driving attention; traders are debating whether it reflects institutional buying or short covering, alongside anticipation of Anktivas FDA label-expansion review and commercial growth. Bullish traders see momentum building, while others caution the rally could fade without concrete news.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is drawing attention after a Vultr order for AMD Helios AI systems and an improved networking growth outlook reinforced the AI data-center demand story. Traders are celebrating the breakout and fresh highs, while others warn the sharp run-up could meet resistance or invite profit-taking.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorths approved merger with Armada II, which is expected to bring a large XRP treasury onto Nasdaq under XRPN, is driving attention alongside a sharp speculative rally. Traders are debating whether tight-float dynamics and the upcoming listing can sustain momentum, while skeptics point to the stocks premium over its expected XRP backing and warn of a pullback.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, range-bound trading and repeated tests of resistance, with chart-focused traders describing consolidation. Some holders expect a breakout and are accumulating, while skeptics point to months of limited progress and question whether token burns or added utility can revive momentum.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Anticipation of a potential Anthropic IPO is the dominant topic, with traders viewing DXYZs Anthropic and other private-tech holdings as a way to gain pre-IPO exposure and debating whether updated valuations could lift its NAV. Bulls expect IPO-related interest to narrow the funds discount, while skeptics point to uncertain timing, limited NAV transparency, and the possibility that the shares may remain discounted or volatile.

TOSHI

TOSHI is drawing attention around hopes for a breakout from its trading range, with traders pointing to rising volume, chart patterns and repeated tests of stubborn resistance while speculating about a short squeeze. Bulls are accumulating and anticipating a rally, while skeptics cite failed breakouts, weak price action and broader crypto-market softness; talk of listings or pending project news remains unverified.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

A volume-backed rally is drawing attention as traders point to PAPZIMEOS commercial momentum and upcoming European regulatory and PRGN-2009 trial updates. Many see heavy short interest as potential fuel, while buyout chatter remains speculative and some investors cite competition from INOVIOs pending FDA decision.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CorMedix (CRMD) Upgraded to Buy: Here's Why

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Biotech Momentum Meets a Google AI Shockwave: 4 Stocks Traders Are Watching Now

Biotech momentum is carrying forward, as the three biotechs we covered, Picard Medical (NYSEAMERICAN:PMI), NeOnc Technologies (NASDAQ:NTHI), and CorMedix (NASDAQ:CRMD) continue to move, while Rezolve Ai (NASDAQ:RZLV) has introduced a powerful new AI infrastructure catalyst through Google (NASDAQ:GOOG).

CorMedix (CRMD) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade

The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

These Stocks are Keeping the Heat Up

The market is once again rewarding companies that can produce a combination of real operating progress, identifiable catalysts and a credible path to growth, including NeOnc (NASDAQ:NTHI), Profusa (NASDAQ:PFSA), CorMedix (NASDAQ:CRMD), IP Strategy (NASDAQ:IPST), Haemonetics (NYSE:HAE), Heartflow (NASDAQ:HTFL), and FreeCast (NASDAQ:CAST).

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat

Equity

CorMedix expects to submit its supplemental Rezzayo application in Q3, with a potential FDA decision in the first half of 2027.

The Stocks Suddenly Giving Traders Something to Chase

The market is delivering a potent mix of earnings acceleration and fresh corporate catalysts can quickly reshape investor expectations. $CRMD, $XHG, $IVDA, $DFSC, $FGI, $ARX

CorMedix Is Printing Cash: CRMD Drops $101.9M Quarter as DefenCath Takes Off

CorMedix Therapeutics (NASDAQ:CRMD) just delivered another powerful quarter, pairing $101.9 million in Q2 revenue with $58.7 million in adjusted EBITDA while expanding DefenCath’s commercial reach and preparing for a potentially major REZZAYO label expansion.

Extremely Bullish Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

CRMD CorMedix Inc